Abstract #2951

NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade

Xavier Chauchet[1*], Sebastien Calloud[1], Pauline LLoveras[1], Nicolas Bosson[1], Margaux Legrand[1], Laura Cons[1], Laurence Chatel[1], Adeline Lesnier[1], Pauline Malinge[1], Guillemette Pontini[1], Christophe Guillamo[1], Oleg Demin Jr[2], Dmitry Shchelokov[2], Ulla Ravn[1], Valéry Moine[1], Bruno Daubeuf[1], Giovanni Magistrelli[1], Yves Poitevin[1], Susana Salgado-Pires[1], Limin Shang[1], Nicolas Fischer, Walter G. Ferlin[1] & Krzysztof Masternak[1]

[1]Light Chain Bioscience – Novimmune SA | Plan-Les-Ouates, Geneva | Switzerland
[2]InsysBio UK Limited, Edinburgh, UK

*Corresponding author: xavier.chauchet@lightchainbio.com

LIGHTCHAIN BIOSCIENCE
A brand of Novimmune SA

Background

- CD47/SIRPa checkpoint blockade has emerged as an effective approach to mobilize myeloid cells to eliminate cancer cells
- Preclinical data have demonstrated the synergistic benefit of combined SIRPa and PD-1 blockade with monoclonal antibodies
- CD47xPD-L1 bsAbs stand as an attractive alternative to mAb combinations, even more so as they provide a solution to improve the safety and PK issues faced by (monospecific) CD47 mAbs, but might also provide superior tumor-targeting capabilities



κλ body platform – Native, human bsAbs

- Native, non-engineered, human bispecific antibodies
- Standard antibody discovery using common heavy chain libraries, kappa and lambda variable light chains drive the specificity to the targets
- Platform purification process, several GMP batches produced
- Two bsAbs in clinical development and multiple κλ body in preclinical development



Fischer *et al.*, Nat. Com., 2015

NI-2901, a CD47xPD-L1 IgG4 κλ body

- **High affinity**
- Blocks PD-1/PD-L1 axis
- Cross-reacts with cynomolgus and mouse



- **Moderate affinity**
- Blocks CD47/SIRPa axis
- Cross-reacts with cynomolgus

- The arms can act independently and also benefit from co-engagement
- Moderate monovalent binding to CD47 on PD-L1-neg cells to mitigate safety concerns
- Stabilized IgG4 and good CMC properties

PD-1/PD-L1 blockade and enhancement of T-cell activation





Weaker binding to CD47-expressing cells as compared to magrolimab





CD47/SIRPa blockade is enhanced by PD-L1 co-engagement





NI-2901 induces robust PD-L1-independent activity

- **Activity in antibody-dependent cellular phagocytosis (ADCP) assays**





- **Antitumor activity in a PD-L1low lymphoma xenograft model**



NI-2901 is well-tolerated and slows down tumor growth in the CD47/PD-L1 humanized MC38 syngeneic model



NI-2901 is well-tolerated in non-human primates

- **Exploratory single-dose (10mg/kg) and multiple dose (30mg/kg) tolerability study**
  - No adverse events were reported with NI-2901
  - No change in body weight, food consumption, clinical chemistry and clinical pathology
  - Red blood cells, platelets and leukocytes remained within the normal range



PK modeling and simulations predict favorable patient dosing regimen



Dosing regimen of magrolimab in clinical trials : 30 mg/kg QW → 30 mg/kg Q2W
Dosing regimen of anti-PD-L1 mAbs: ≈10 mg/kg Q2W or 15 mg/kg Q3W

Conclusions

- **NI-2901 (IgG4 CD47xPD-L1 bispecific antibody):**
  - Enhances phagocytosis of tumor cells, increases T-cell activation and demonstrates antitumor activity *in vivo*
  - Well tolerated in non-human primates following weekly doses over 28 days (30mg/kg, highest dose tested)
  - Favorable patient dosing regimen is predicted by PK modeling and simulation

AACR Annual Meeting 2023, April 14-19, Orlando, USA